Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

APPY 0.337 +0.037 (12.43%)
price chart
INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced By Glancy ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of a class (the “Class”) comprising purchasers of the securities ...
Company Shares of Venaxis, Inc. (NASDAQ:APPY) Drops by -1.69%
Venaxis, Inc. (NASDAQ:APPY) has lost 1.69% during the past week and dropped 18.57% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 3.68%.
Company Shares of Venaxis, Inc. (NASDAQ:APPY) Rally 4.7%
Shares of Venaxis, Inc. (NASDAQ:APPY) rose by 4.7% in the past week and 8.16% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 8.39% and the outperformance increases to 16.96% for the last 4 weeks.
Venaxis Inc (APPY) Stock Crashes On FDA's “Not Substantially Equivalent” Response
Venaxis Inc (NASDAQ:APPY) has received "not substantially equivalent" remarks on its blood-based diagnostic test, APPY1, from the US Food and Drug Administration (FDA).
Venaxis' appendicitis test not found equivalent to standard care  Reuters
Venaxis Receives FDA "Not Substantially Equivalent" Response on ...  PR Newswire (press release)
Today's Pre-Market Ratings: RENN Fund, Inc. (RCG), Venaxis, Inc. (APPY ...
RENN Fund, Inc. (RCG) from the USA finished up on Mon with a 7-day performance of -0.97% ending the day at $1.02, up 4.08%.
Venaxis Business Update
CASTLE ROCK, Colo., June 22, 2015 /PRNewswire/ -- Venaxis�, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children, adolescent, ...
Venaxis Inc (NASDAQ:APPY) a Hold: Canaccord Genuity
In a research note issued to investors, Mark Massaro at Canaccord Genuity Reiterated their Hold rating on Venaxis Inc (NASDAQ:APPY).
Why Numerous Upside Scenarios Make Venaxis A Biotech To Buy (APPY)
With news being very light on names that I cover over the past few weeks, I wanted to initiate a new name today: Venaxis (NASDAQ:APPY).
Undiscovered Jewels? ADTRAN, Inc. (ADTN) and Venaxis Inc (APPY)
Venaxis Inc (NASDAQ:APPY) plummeted yesterday as the stock lost fourteen cents to finish the day at a closing price of $0.56, a 20.14% decline in value from its previous closing price on heavy trading volume of 3.418 million shares, compared to its ...
What to know Thurs: Aclaris Therapeutics, Inc. (ACRS), Venaxis, Inc. (APPY ...
Aclaris Therapeutics, Inc. (ACRS) from the USA performed poorly at the end of the day yesterday with a 7 day performance of -4.09% closing at $14.31, a loss of -2.39%.